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This paper  assesses  whether  the  concession  card, which  offers  discounted  out-of-pocket
costs  for  prescription  medicines  in  Australia,  affects  discontinuation  and  adherence  to  statin
therapy. The  analysis  uses  data  from  the  Australian  Hypertension  and Absolute  Risk  Study
(AusHEART),  which  involves  patients  aged  55 years  and  over  who  visited  a GP  between  April
and June  2008.  Socioeconomic  and  clinical  information  was  collected  and  linked  to admin-
istrative  data  on  pharmaceutical  use.  Patients  without  a concession  card  were  63%  more
likely (hazard  ratio  (HR)  95%  conﬁdence  interval  (CI):  1.14–2.33)  to discontinue  and  60%
(odds ratio  (OR)  CI: 1.04–2.44)  more  likely  to  fail to adhere  to  therapy  compared  to  conces-
sional  patients.  Smokers  were  2.12  (HR  CI: 1.39–3.22)  times  more  likely to  discontinue  useAdherence
Discontinuation
Australian Pharmaceutical Beneﬁts Scheme
and 2.23  (OR  CI: 1.35–3.71)  times  more  likely  to  fail  to adhere  compared  to non-smokers.
Patients  who  had  recently  initiated  statin  medication  were  also  2.28  (HR CI: 1.22–4.28)
times  more  likely  to  discontinue  use.  In conclusion,  higher  copayments  act  as  a disincentive
for  persistent  and  adherent  use  of  statin  medication.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
1. Introduction
As with many developed countries, deaths from car-
diovascular disease (CVD) remains Australia’s leading
cause of death, with 32% caused by CVD in 2010 [1]. The
past two decades has witnessed the widespread use of
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statin medications to treat patients at elevated risk of CVD
with the total volume of prescriptions dispensed through
the Pharmaceutical Beneﬁts Scheme (PBS) increasing
from around 2 million in 1992 to 22 million in 2011
[2]. Statin medication has been shown to signiﬁcantly
improve survival and reduce the likelihood of future
CVD events when used in both primary and secondary
prevention [3]. Although the prescribing of statins is
widespread, discontinuation is high and adherence to
treatment is low [4,5,26,27], and have been shown
to lead to increased hospitalization rates and medical
costs [6].
A recent Australian study examined the effect of sin-
gle and combination therapies involving atorvastatin on
persistence, revealing high rates of discontinuation of
is is an open access article under the CC BY-NC-ND license
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statin therapy at the time of consultation. We  deduced aR.J. Knott et al. / Healt
reatment especially when the drug was taken with other
herapies as separate tablets (as opposed to combination
ablets) [7]. One factor that may  account for higher per-
istence when using combination therapy is the lower
ut-of-pocket costs consumers face, as there is consider-
ble evidence, mainly from North America that costs to the
atient can impact long-term and adherent use of cardio-
ascular drugs [8–10].
An issue with the design of all health insurance sys-
ems is in setting levels of patient contributions through
o-payments or deductibles [11]. Most countries that sub-
idize the cost of pharmaceuticals, including Australia,
ncrease access to disadvantaged populations such as low-
ncome households and those on state pensions by further
educing or eliminating co-payments for these groups [12].
utside of North America there is little evidence whether
hose receiving additional beneﬁts are more adherent to
rescribed medications.
The Australian government subsidizes the cost of a
ide range of pharmaceuticals for all Australian residents
hrough the PBS, and promotes access to aged and dis-
dvantaged groups through the concession card. Patients
ho hold a concession card (pensioners, unemployed and
ligible low income households) face a signiﬁcantly dis-
ounted price compared to general users (e.g. ordinary
opayments in 2009 were $5.30 for concessional users,
ompared to $32.90 for general users). Individuals who
ave high pharmaceutical expenditure are also protected
hrough a Safety Net,  which involves reduced co-payment
ates for patients that exceed a threshold level of expen-
iture in a calendar year (e.g. in 2009 for general users
he co-payments decreased to $5.30 after they incurred
1264.90 of pharmaceutical expenditure and for conces-
ional users there was no co-payment after $318.00 of
xpenditure) [13].
The aim of this study is to investigate the relative dis-
ontinuation and adherence failure rates of concessional
s. general users for patients prescribed statins. Our sample
omes from the Australian Hypertension and Absolute Risk
tudy (AusHEART) with linked administrative data from
edicare which contains records of all pharmaceuticals
urchased under the PBS. We  also control for clinical and
atient characteristics.
. Methods
.1. Study overview
The AusHEART study has been described previously
14,15]. In brief, the study recruited 322 GPs across
ustralia in a randomized, stratiﬁed manner. GPs were
sked to provide clinical information on 15–20 consecu-
ively presenting, consenting patients aged 55 years and
ver, irrespective of the reason for the consultation, who
resented between April and July 2008. Patients com-
leted a one-page questionnaire on self perceived health,
isk behaviors such as smoking and socioeconomic fac-
ors. Patients were also given the option to consent to
aving their information linked with Medicare Australia
dministrative data. The study was approved by the 119 (2015) 620–627 621
Royal Australian College of General Practitioners National
Research and Evaluation Ethics Committee.
2.2. Patient eligibility criteria
AusHEART patients were eligible if they consented to
their data being linked to their Medicare records, and had
evidence of statin use from PBS records within the ﬁrst
year following survey completion (i.e. time of GP consulta-
tion). Our statin use observation period commenced from
the date the patient ﬁlled their ﬁrst statin prescription fol-
lowing survey completion, and concluded one year after
survey completion. Note that since the PBS only records
information on medications that attract a subsidy, we do
not have information on medications priced below rele-
vant patient copayments. For example, the total price of
Simvastatin 10 mg  in 2009 was  around $24 which is below
the ordinary non-concessional co-payment and so do not
appear in the PBS data for these patients. To ensure compa-
rability of concessional and general patients we removed
all individuals who  had evidence of any use of these low-
cost statins i.e. Simvastatin 5 mg/10 mg,  Pravastatin 10 mg,
Fluvastatin 20 mg/40 mg.  We  examined the effects of this
exclusion in a sensitivity analysis.
2.3. Patient-provided information
We  used information on self-perceived health, risk
behaviors, and socioeconomic factors as stated in the
patient-completed questionnaire. Patients reported their
gross household income according to one of seven cat-
egories ranging from negative/nil income to $2000 or
more per week. We applied Organization for Economic
Cooperation and Development equivalence weights to
adjust income (measured at the mean of the bounds of
each income category) for household composition, where
a value of 1 was  assigned to the household head, 0.5 to each
additional adult, and 0.3 to each child [16]. Patients were
then divided into income quartiles based on calculated
equivalized income. Other information from the patient-
completed survey used in the analysis included age, sex,
self-reported health (measured on a ﬁve-point scale, from
excellent to poor), self-perceived CVD risk (measured on
a six-point scale from no chance to very high chance of a
CVD event in the next ﬁve years), and smoking status.
2.4. Doctor-provided information
GPs completed a questionnaire containing medical
history of the patient and clinical information mainly
related to the patient’s CVD risk. Information reported
by the GP used in this study included an estimation of
the patient’s absolute cardiovascular risk; the presence of
chronic kidney disease (CKD), diabetes, and established
CVD; height and weight of the patient to calculate body
mass index; and whether the patient was  initiated onproxy for locality type (metropolitan, regional or remote)
from the GP practice’s postcode using the Australian
Standard Geographical Classiﬁcation – Remoteness Area
(ASGC-RA) correspondences [17].
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2.5. Administrative data
The Medicare administrative data contained records of
all pharmaceuticals purchased under the PBS and all ser-
vices provided under the Medicare Beneﬁts Scheme (MBS)
from 1 March 2008 to 1 January 2010. Each PBS entry
recorded the item number and description, the Anatomical
Therapeutic Chemical (ATC) classiﬁcation code and name,
and the date of prescription and supply. PBS records divided
payments for pharmaceuticals into ‘net beneﬁts’ (govern-
ment contributions) and patient contributions (the sum
of which is the total cost of the drug). The beneﬁciary
type of the patient was also speciﬁed for each purchase
(i.e. general patients, concessional patients (those on a rele-
vant pension or with a Commonwealth Seniors Health Card
which is means tested, and/or eligible low income families),
general safety-net patients (general patients who reached
a speciﬁed annual threshold during a calendar year) and
concessional safety-net patients (concessional patients who
reached a discounted threshold during a calendar year))
[13].
Entries for statins (including statin combination ther-
apy) were identiﬁed from ﬁfth-level ATC codes (i.e.
chemical substance) [18]. We  also used Medicare records
to identify patients who received treatment for cancer or
mental health conditions, and the number of medication
types used according to ATC level 1 classiﬁcations. We  iden-
tiﬁed the presence of mental health conditions based on
MBS  item numbers for GP mental health-care plans, psychi-
atric attendances and psychological therapy services; and
treatment for cancer using MBS  and PBS data (including
the Section 100 Highly Specialised Drugs Program) based
on item numbers for chemotherapy, radiation oncology,
nuclear medicine procedures, and prescriptions for Anti-
neoplastic and immunomodulating agents.
3. Statistical analysis
3.1. Sample comparisons
The characteristics of the patients who consented to
Medicare linkage were compared with those who did not
using t-tests for continuous variables and z tests for binary
variables. Similarly, t-tests/z tests were used to compare
the characteristics of concession and non-concession users
in the sample used in the analysis.
3.2. Discontinuation
To determine whether patients discontinued statin
therapy we used the date and quantity supplied for each
statin prescription to calculate the ﬁnal date of statin pos-
session during the study period (in a cumulative manner
to avoid overestimation of supply due to the effects of
stock-piling). If the ﬁnal date of possession was before the
end of our study window, the patient was considered to
have discontinued therapy at this date. Note that patients
who stopped taking statins and then restarted therapy
sometime later (within the observation window) were not
considered to have discontinued treatment, unless they 119 (2015) 620–627
stopped treatment again and did not restart before the end
of the observation window.
The inﬂuence of concessional status on discontinuation
was  examined using a Cox proportional hazards model.
During the observation period the prices of Pravastatin
20 mg  and Simvastatin 20 mg  decreased below the maxi-
mum  patient copayment (i.e. the price of Pravastatin 20 mg
decreased below $31.90 in August 2008, and the price
of Simvastatin 20 mg  decreased below $32.90 in January
2009). We  therefore censored patients using these drugs
(who did not change to a higher priced statin before the
price change) at the time of the respective price changes.
Since this was  an older population, we  also censored
patients that did not have any Medicare records (neither
MBS  nor PBS) in the last three months of the observation
period (and beyond), under the assumption that they may
have died or relocated overseas.
3.3. Adherence failure
Adherence was  deﬁned using the proportion of days
covered (PDC) method. The PDC is the number of days with
statins on hand over a given time period [19]. The time
period commenced from the date of the ﬁrst statin sup-
ply during the study window and ended at the ﬁnal date
of statin possession (or at the end of the 12-month obser-
vation period: whichever date came ﬁrst). For consistency
of interpretation of results with those for discontinuation,
we deﬁne a binary variable representing adherence fail-
ure. A patient was  considered to fail to adhere to therapy
if they possessed statins for less than 80% of days in this
period [20,21]. We  assessed the impact of the concession
card and other factors on adherence failure using univariate
and multiple logistic regression.
3.4. Model estimation
The impact of the concession card on discontinua-
tion and adherence failure was  examined in univariate,
multivariate unrestricted (all control variables included)
and multivariate restricted models (only signiﬁcant con-
trol variables included). Control variables included age,
sex, income quartile, education, marital status (married/de
facto or alone), location (metropolitan or regional/remote),
self-reported health, patient and GP perception of the
patient’s CVD risk, smoking status, and whether statins
were initiated during the study consultation. Since adher-
ence and persistence may  be inﬂuenced by overall drug
costs and treatment burden in general, we  also included
indicators for CVD, diabetes, CKD, cancer and mental health
conditions, as well as the total number of medication types
ﬁlled per patient according to ATC level 1 classiﬁcations
(i.e. major categories). Selection for variable inclusion in
the restricted models was based on forward and backward
stepwise elimination (at the 5% level of signiﬁcance), using
robust standard errors clustered by GP practice. The Cox
regression coefﬁcients for discontinuation are presented as
hazard ratios and logistic regression coefﬁcients for adher-
ence failure are presented as odds ratios. We  also report
95% conﬁdence intervals (CIs).
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. Results
Of the 5293 patients who participated in the AusHEART
tudy, 3538 consented to linkage with Medicare records.
ompared to the sample who did not consent to data
inkage, those that consented were on average more
ikely to be married or in a de facto relationship (68%
s. 65%; P = 0.0096), have slightly higher mean systolic
lood pressure (136 vs. 135; P = 0.0452) and more likely
o be obese (36% vs. 33%; P = 0.0321). After excluding 691
atients who did not provide information on relevant
ariables used in this analysis, we identiﬁed 1315 patients
ho ﬁlled prescriptions for statins within 12 months of
heir consultation date. A further 55 people were removed
s they had evidence of low-cost statin use (i.e. statins
riced below the maximum patient copayment) leaving
260 in the ﬁnal sample. Characteristics of our sample are
resented in Table 1, along with characteristics by beneﬁ-
iary type. Of the identiﬁed statin users, 12% discontinued
tatin therapy during the observation window and 9%
ailed to adhere while on therapy. Compared to general
sers, those who had a concession card (80% of users)
ere on average older, had signiﬁcantly lower incomes
nd had lower levels of education. The prevalence of
stablished CVD, established chronic kidney disease, and
elow average self-assessed health was almost twice as
igh amongst concession users. This group also used more
ypes of medications on average over the study period
able 1
haracteristics of sample used in analysis.a
Variable All stat
N  = 126
Personal/demographic characteristics
Male 630 (5
Age (years) 68 ± 8b
Regional 481 (3
Married or de factor 882 (7
Socioeconomic information
Total yearly equivalized household income ($) 23,459
Has university degree 215 (1
Health and risk behavior information
Diabetes 441 (3
Established cardiovascular disease 520 (4
Chronic kidney disease 97 (8%
Cancer 51 (4%
Mental health issues 81 (6%
Low-density lipoprotein (mmol/L) 2.54 ± 
Systolic blood pressure (mmHg) 136 ± 1
Diastolic blood pressure (mmHg) 75.20 ±
Below average self-reported health 400 (3
Current smoker 109 (9
Obese  (BMI ≥ 30 kg/m2) 508 (4
Statin therapy/concession information
Initiated statin therapy at time of AusHEART data collection 50 (4%
On  statin combination therapy 120 (1
Number of medication types according to ATC level 1 classiﬁcations 3.34 ± 
Discontinued statin therapy 147 (1
Failed to adhere to statin therapy 117 (9
Concessional user 1004 (
a t-Tests were used to compare continuous variables and z tests for binary vari
b Age, income, low-density lipoprotein, systolic blood pressure,diastolic blood
alues.
* t-Tests/z-tests indicated variable means/proportions for concession and gene 119 (2015) 620–627 623
compared to non-concession users, according to ATC level 1
classiﬁcations.
The results of univariate and multivariate analysis of
factors associated with discontinuation are reported in
Table 2. 131 (10%) patients were censored earlier than 12
months due to either not having any Medicare records
in the last three months of the observation period or
beyond (13 people), or because they had evidence of the
use of Pravastatin 20 mg  or Simvastatin 20 mg and did
not change to a higher priced statin before the associ-
ated price change (24 and 94 patients, respectively). In the
restricted multivariate model, ordinary patients (i.e. those
who did not have a concession card) were 1.63 (95% CI:
1.14–2.33) times more likely than concession users to dis-
continue use. Furthermore, at the end of the 12 month
period, there was around 7% difference in discontinua-
tion between concessional and general users (Fig. 1). Statin
users whose therapy was initiated at the time of consul-
tation were 2.28 (95% CI: 1.22–4.28) times more likely
to discontinue medication compared to those who had
previously commenced therapy while smokers were 2.12
(95% CI: 1.39–3.22) times more likely to discontinue com-
pared to non-smokers. Univariate analysis and multivariate
unrestricted analysis yielded similar results. There was no
signiﬁcant evidence that the odds of discontinuing therapy
varied with CVD risk perception, comorbidities, number of
medication types used, socioeconomic characteristics, or
the use of combination therapies.
in users Concession users General users
0 n = 1004 n = 257
0%) 483 (48%) 147 (57%)*
70 ± 8 62 ± 6*
8%) 405 (40%) 76 (30%)*
0%) 683 (68%) 199 (78%)*
.25 ± 18,952.05b 17,804.65 ± 13,049.75 45,635.90 ± 21,997.95*
7%) 126 (13%) 89 (35%)*
5%) 361 (36%) 80 (31%)
1%) 457 (46%) 63 (25%)*
) 88 (9%) 9 (4%)*
) 42 (4%) 9 (4%)
) 67 (7%) 14 (5%)
0.93b 2.51 ± 0.92 2.65 ± 0.97*
7b 136 ± 17 134 ± 16*
 10.13b 74.57 ± 10.17 77.67 ± 9.61*
2%) 352 (35%) 48 (19%)*
%) 83 (8%) 26 (10%)
0%) 393 (39%) 111 (43%)
) 36 (4%) 14 (5%)
0%) 92 (9%) 28 (11%)
0.09 3.31 ± 0.09 4.80 ± 0.73*
2%) 104 (10%) 43 (17%)*
%) 84 (8%) 33 (13%)*
80%)
ables.
 pressure and number of medication types are presented as mean ± SD
ral users differed signiﬁcantly at 5% level of signiﬁcance.
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Table 2
Hazard ratio and 95% conﬁdence intervals for discontinuation of statin therapy (failure = discontinuation).
Univariate analysis Multivariate analysis:
unrestricted model
Multivariate analysis:
restricted model
Male 1.09 (0.76–1.55) 1.03 (0.69–1.55)
Female 1.00 1.00
Age 1.00 (0.97–1.02) 1.02 (0.99–1.05)
Location
City  1.00 1.00
Regional/Remote 0.95 (0.68–1.34) 0.97 (0.69–1.37)
Married/de facto
Yes 0.98 (0.67–1.42) 1.10 (0.73–1.65)
No  1.00 1.00
Income quartile
1st (lowest) 1.00 1.00
2nd 0.82 (0.51–1.30) 0.80 (0.49–1.31)
3rd  1.37 (0.89–2.12) 1.28 (0.82–2.02)
4th  (highest) 1.15 (0.74–1.77) 0.94 (0.56–1.59)
Has  university degree
Yes 0.87 (0.54–1.40) 0.76 (0.44–1.30)
No  1.00 1.00
CVD
Yes 0.89 (0.63–1.27) 0.94 (0.63–1.41)
No  1.00 1.00
Diabetes
Yes 0.83 (0.58–1.21) 0.84 (0.57–1.24)
No  1.00 1.00
Kidney disease
Yes 1.43 (0.83–2.48) 1.56 (0.87–2.79)
No  1.00 1.00
Cancer
Yes  0.89 (0.36–2.24) 0.95 (0.38–2.37)
No  1.00 1.00
Mental health conditions
Yes 0.92 (0.39–2.18) 0.88 (0.37–2.09)
No  1.00 1.00
Self-reported health
Excellent, Very good, Good (combined) 1.00 1.00
Below average (Fair and Poor combined) 0.99 (0.70–1.41) 1.04 (0.69–1.56)
Number of ATC level 1 medications 0.94 (0.87–1.02) 1.00 (0.90–1.10)
Patient perception of their CVD risk
Low 1.00 1.00
Moderate 0.84 (0.59–1.20) 0.83 (0.57–1.19)
High  1.13 (0.59–2.18) 1.15 (0.55–2.40)
GP  perception of patient’s CVD risk
Low 0.86 (0.48–1.54) 0.73 (0.40–1.33)
Moderate 1.01 (0.54–1.92) 0.89 (0.48–1.67)
High  1.16 (0.66–2.06) 0.99 (0.54–1.80)
No  response 1.00 1.00
Current smoker
Yes 2.19 (1.44–3.34)*** 2.28 (1.44–3.61)*** 2.12 (1.39–3.22)***
No 1.00 1.00
Obese
Yes 0.80 (0.58–1.10) 0.84 (0.59–1.18)
No  1.00 1.00
Statin therapy initiated at time of AusHEART survey
Yes 2.46 (1.33–4.52)*** 2.00 (1.01–3.96)** 2.28 (1.22–4.28)**
No 1.00 1.00
On statin combination therapy
Yes 0.75 (0.42–1.36) 0.73 (0.40–1.33)
No  1.00 1.00
Concession user
Yes 1.00 1.00 1.00
No  1.69 (1.19–2.40)*** 1.98 (1.15–3.41)** 1.63 (1.14–2.33)***
n = 1252.
95% conﬁdence intervals are displayed in brackets.
Standard errors are clustered by GP.
Note: 131 patients were censored earlier than 12 month due to either not having any Medicare records in the last three months of the observation period or
beyond  (13 people), or because price of the statin they were prescribed dropped below non-concessional co-payment (118 patients). Selection for variable
inclusion in the restricted model was based on forward and backward stepwise elimination (at the 5% level of signiﬁcance), which give identical results.
**P < 0.05.
***P < 0.01.
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Table  3
Logistic regression odds ratios and 95% conﬁdence intervals for adherence failure to Statin therapy.
Univariate analysis Multivariate analysis:
unrestricted model
Multivariate analysis:
restricted model
Male 0.95 (0.66–1.36) 0.99 (0.66–1.47)
Female 1.00 1.00
Age 0.98 (0.96–1.01) 1.00 (0.97–1.03)
Location
City  1.00 1.00
Regional/Remote 1.01 (0.69–1.50) 1.03 (0.70–1.51)
Married/de facto
Yes 0.88 (0.58–1.34) 0.82 (0.52–1.30)
No  1.00 1.00
Income quartile
1st (lowest) 1.00 1.00
2nd 1.07 (0.66–1.73) 1.11 (0.65–1.90)
3rd  1.07 (0.63–1.83) 0.97 (0.56–1.68)
4th  (highest) 1.28 (0.77–2.14) 1.30 (0.70–2.41)
Has  university degree
Yes 0.69 (0.41–1.18)* 0.56 (0.31–1.01)*
No 1.00 1.00
CVD
Yes 0.84 (0.57–1.25) 0.93 (0.61–1.42)
No  1.00 1.00
Diabetes
Yes 0.88 (0.58–1.34) 0.87 (0.56–1.36)
No  1.00 1.00
Kidney disease
Yes 0.87 (0.41–1.83) 1.02 (0.47–2.20)
No  1.00 1.00
Cancer
Yes  0.83 (0.30–2.28) 0.91 (0.32–2.52)
No  1.00 1.00
Mental health conditions
Yes 1.78 (0.88–3.58) 1.64 (0.82–3.28)
No  1.00 1.00
Self-reported health
Excellent, Very good, Good (combined) 1.00 1.00
Below average (Fair and Poor combined) 0.91 (0.59–1.41) 0.89 (0.55–1.42)
Number of ATC level 1 medications 0.96 (0.88–1.04) 1.02 (0.91–1.14)
Patient perception of their CVD risk
Low 1.00 1.00
Moderate 1.15 (0.72–1.83) 1.08 (0.66–1.76)
High  0.95 (0.42–2.13) 0.91 (0.39–2.14)
GP  perception of patient’s CVD risk
Low 0.73 (0.38–1.43) 0.65 (0.34–1.28)
Moderate 0.77 (0.36–1.65) 0.70 (0.32–1.54)
High  0.82 (0.42–1.60) 0.74 (0.36–1.50)
No  response 1.00 1.00
Current smoker
Yes 2.27 (1.37–3.74)*** 2.16 (1.27–3.67)*** 2.23 (1.35–3.71)***
No 1.00 1.00
Obese
Yes 1.32 (0.90–1.95) 1.39 (0.92–2.11)
No  1.00 1.00
Statin therapy initiated at time of AusHEART survey
Yes 1.63 (0.77–3.46) 1.39 (0.63–3.06)
No  1.00 1.00
On statin combination therapy
Yes 0.88 (0.42–1.85) 0.83 (0.39–1.80)
No  1.00 1.00
Concession user
Yes 1.00 1.00 1.00
No  1.62 (1.07–2.45)** 1.78 (0.91–3.49)* 1.60 (1.04–2.44)**
N = 1260.
95% conﬁdence intervals are displayed in brackets.
Standard errors are clustered by GP.
Note that estimating adherence using a continuous rather than binary measure found a similar result. Selection for variable inclusion in the restricted
model was  based on forward and backward stepwise elimination (at the 5% level of signiﬁcance), which give identical results.
* P < 0.1.
** P < 0.05.
*** P < 0.01.
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3 peopFig. 1. Persistence in use of statins after GP consultation. Note: 131 patie
records in the last three months of the observation period or beyond (1
non-concessional co-payment (118 patients).
Table 3 presents the results of the logistic regression
models for adherence failure. In the restricted model,
patients who did not have a concession card were 1.60
(95% CI: 1.04–2.44) times more likely to fail to adhere to
statin therapy compared to concession users and smokers
were 2.23 (95% CI: 1.35–3.71) times more likely to fail to
adhere compared to non-smokers. No other variables were
found to signiﬁcantly affect adherence failure in multivari-
ate or univariate models, with the exception of education
which was weakly signiﬁcant in the unrestricted multivari-
ate model (people who had a university degree were 56%
[95% CI: 0.31–1.01] more likely to fail to adhere to therapy
when all other variables were controlled for).
A sensitivity analyses involving all identiﬁed statin
users (i.e. inclusive of those who were removed due to evi-
dence of low-cost statin use), found no changes to overall
signiﬁcance of results and the maximum change in the size
of any coefﬁcient was less than 5%.
5. Discussion
This study has examined how the concession card
impacted on discontinuation and adherence failure to
statin medication which is commonly used in primary
and secondary prevention of CVD. PBS concession card
users had a signiﬁcantly higher degree of continuation and
adherence to statin therapy compared to general users,
even after controlling for income, education and a range of
clinical factors. These ﬁndings suggest that the higher out-
of-pocket costs associated with not having a concession
card impacted on the frequency and continuation of dis-
pensing of prescriptions for these cardiovascular drugs and
may lead to higher levels of morbidity and mortality among
these patients. We  also found that smokers were signiﬁ-
cantly less likely to continue and adhere to statin therapy,
which may  reﬂect their time preferences for health and/or
attitudes toward risk.
The ﬁndings of this study are consistent with a previ-
ous study using aggregate PBS data before and after the
rise in PBS co-payments in 2005 [22] which showed that
dispensing volumes signiﬁcantly decreased in 12 of the
17 medicine categories including statin medications. Thee censored earlier than 12 month due to either not having any Medicare
le), or because price of the statin they were prescribed dropped below
overall cost and out-of-pocket payments for pharmaceut-
icals such as statins are relatively high in Australia [12,23],
so most non-concessional patients faced co-payments of
more than $30 per month for these drugs during the study
period. The impact of a recent proposal to further increase
co-payments for general users by $5 would likely have a
negative impact on adherence [24].
In regard to policy implications, reducing high levels of
co-payments are likely to improve continuation and adher-
ence and hence health outcomes across the population.
However, the recent reductions in the price of most statins
following patent expiry should improve adherence among
non-concessional users as the cost of many of these drugs is
now below the level of co-payment examined in this study
(e.g. Simvastatin 40 mg  is now only $12). It may  also be
worth educating smokers on the beneﬁts of treatments and
the risks associated with adherence failure and discontin-
uation of therapy.
An advantage of the AusHEART study is that it collected
socioeconomic and clinical information that was linked
to administrative data on pharmaceutical drug use. This
allowed the tracking of prescriptions during the follow-up,
obviating the need to obtain this information through less
reliable means such as self-report.
Our study has several limitations which should be con-
sidered. Firstly, our study examines patients aged 55 years
and over who  attended a GP and consented to linkage with
Medicare records. We  experimented with weighting the
regressions by a factor of GP consultations per patient how-
ever this made no difference to our conclusions. Secondly,
most patients in our sample (96%) commenced statin ther-
apy prior to our observation period and so we  could not
include information on lipid levels or estimated CVD risk
at the time of the GP consultation as reverse causality (i.e.
lipid levels of patients already on statins are therapeuti-
cally lowered) would likely confound the results. Thirdly,
our persistence levels are likely to be much higher than
if we were able to observe patients from when they ﬁrst
commenced therapy, as many studies ﬁnd that patients dis-
continue use shortly after commencing therapy for the ﬁrst
time, [28,29] which was  conﬁrmed by our analysis. More-
over, adherence rates have also been shown to be higher for
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ut-of-pocket costs are even more important in this early
eriod. Fourthly, we do not know whether statins were
ctually consumed, or when they were consumed; we only
now when prescriptions were ﬁlled. Finally, some patients
ay have ceased taking statins because they switched to
ther lipid lowering medications. We  have not been able to
nvestigate this matter due to issues with double-counting
n the case that alternative medicines are used in conjunc-
ion with statins (but as different pills), or if they are used
or purposes other than lowering cholesterol.
In conclusion, we have shown that higher copayments
ct as a disincentive for persistent and adherent use of
tatin medication. Reducing out-of-pocket costs may  not
nly increase affordability, but also lead to reduced lev-
ls of morbidity and mortality through improved rates of
dherence and continuation of therapy.
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